Senzime Ab Stock Price, News & Analysis

Senzime (OTCQX:SNZZF) announced an order for 70 TetraGraph systems from a leading UK NHS hospital trust to standardize neuromuscular monitoring across major operating rooms. The contract, secured via partner Healthcare 21, targets full implementation annual usage of more than 15,000 TetraSens sensors. Management called this its largest TetraGraph order in Europe and highlighted UK guidelines from the Association of Anaesthetists recommending quantitative monitoring in every operating theatre whenever neuromuscular blocking drugs are used. The TetraGraph system is used globally to support timing of intubation, individualized dosing, reversal decisions, and safe tracheal extubation.

Senzime (SNZZF) has announced two major initiatives to advance anesthesia monitoring practices: the launch of a new Medical Affairs division and the Senzime Academy education platform. The Medical Affairs division, led by Jen Sanders, will focus on collaborating with academic centers and healthcare providers to translate clinical research into practice and address residual neuromuscular block (rNMB) risks.

The company's TetraGraph system, backed by 40+ years of research and featured in 19 peer-reviewed publications, is currently utilized in over 3,500 operating rooms globally. The system's EMG-based platform supports compliance with ASA and ESAIC best practices. The new Senzime Academy offers on-demand training for clinicians on quantitative train-of-four (TOF) monitoring and TetraGraph implementation across adult and pediatric care settings.

Senzime reported strong Q3 2024 financial results with net sales of 17.4 MSEK, up 90% year-over-year. Sales of disposable sensors surged 169% to 12.5 MSEK, while US sales grew 81% to 13.1 MSEK. The company's TetraGraph system has been installed in over 500 hospitals globally. Despite growth, operating costs increased to 38.4 MSEK, resulting in an operating loss of 26.5 MSEK. The company recently launched its next-generation TetraGraph at ANESTHESIOLOGY 2024, featuring Adaptive Intelligence technology. Cash position stood at 50.2 MSEK as of September 30, 2024.

Senzime AB has announced changes in its share structure during October 2024. The company completed a directed share issue of 12,769,000 shares, increasing the total number of shares from 119,705,523 to 132,474,523. The share capital has risen to SEK 16,559,315.375 from SEK 14,963,190.375. An additional 1,104,000 shares from another directed share issue are pending registration following approval at the extraordinary general meeting on October 23, 2024. The company currently holds no treasury shares.

Senzime (SNZZF) has announced a webcast presentation of its Q3 2024 report scheduled for November 6, 15:00 CET. The report will be published earlier the same day. CEO Philip Siberg will lead the presentation, followed by a Q&A session moderated by Carnegie Investment Bank analyst Klas Palin. The presentation will be conducted in English and last 30 minutes. Participants can submit questions in advance via email to the moderator before 12:00 CET on November 6. The presentation will be available on Senzime's investor relations website.

Senzime has unveiled its next-generation TetraGraph® system at ANESTHESIOLOGY® 2024, featuring advanced monitoring capabilities for neuromuscular block during surgery. The system includes TetraGraph® Adaptive Intelligence™, offering automated workflows and real-time data monitoring. Key improvements include a revolutionary user interface with Level-of-Block Gauge™ and a 6th generation EMG algorithm with 4x higher resolution. The company announced that U.S. shipments will begin in Q4 2024, with the system designed to reduce complications from residual neuromuscular block in surgical patients.

At Senzime AB's extraordinary general meeting on October 23, 2024, shareholders unanimously approved the board's resolution for a directed share issue originally decided on September 27, 2024. The issue comprises a maximum of 1,104,000 shares at a subscription price of SEK 6.20 per share, with subscription rights granted to Adam Dahlberg and Sorin J. Brull. This will increase the company's share capital by up to SEK 138,000. The subscription deadline is set for October 28, 2024, and payment must be made in cash.

Senzime has secured its first order for the next-generation TetraGraph system from a Swiss hospital, comprising 20 monitors for Q1 2025 delivery with expected revenues of SEK 3 million over three years, including disposable sensors. The system, launched at ANESTHESIOLOGY 2024, features advanced monitoring capabilities including the Level-of-Block Gauge™, Adaptive Intelligence™, and an improved EMG algorithm with 4x higher resolution. The technology aligns with new clinical guidelines requiring quantitative monitoring of neuromuscular blocking drugs used in approximately 100 million surgical procedures annually.

A new US-based clinical study has validated the accuracy of Senzime's TetraGraph system, a neuromuscular monitoring device. The study, published on October 18, 2024, in the Journal of Clinical Monitoring and Computing, compared the TetraGraph to benchmark mechanomyography (MMG) technology. Key findings include:

1. The TetraGraph demonstrated 97.9% accuracy compared to MMG.
2. It is the first study to clinically validate a portable EMG-only system at all levels of neuromuscular block.
3. Results suggest TetraGraph's performance is superior to other commercially available neuromuscular monitoring systems.
4. The study was conducted at the Medical College of Wisconsin, led by Prof. Thomas Ebert.

Senzime's Chief Medical Officer, Dr. Sorin J. Brull, emphasized the importance of the TetraGraph's precision, particularly during laparoscopic and robotic surgeries. The researchers concluded that EMG monitors like TetraGraph should become a clinical standard for all phases of neuromuscular block.